[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @JamesEKrause Biotech Jim Biotech Jim posts on X about $mdgl, $regn, $srpt, $abvx the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1091405261741404162/interactions)  - X Week XXXXXX +182% - X Month XXXXXX +148% - X Months XXXXXXX -XX% - X Year XXXXXXX +42% ### Mentions: XX [#](/creator/twitter::1091405261741404162/posts_active)  - X Months XX -XX% - X Year XXX +120% ### Followers: XXXXXX [#](/creator/twitter::1091405261741404162/followers)  - X Week XXXXXX +0.50% - X Month XXXXXX +1.60% - X Months XXXXXX +7.90% - X Year XXXXXX +16% ### CreatorRank: XXXXXXX [#](/creator/twitter::1091405261741404162/influencer_rank)  ### Social Influence [#](/creator/twitter::1091405261741404162/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [agencies](/list/agencies) **Social topic influence** [$mdgl](/topic/$mdgl) #4, [$regn](/topic/$regn), [$srpt](/topic/$srpt), [$abvx](/topic/$abvx) #48, [$crvs](/topic/$crvs), [$nktr](/topic/$nktr), [drugs](/topic/drugs), [$axsm](/topic/$axsm), [$951m](/topic/$951m), [investment](/topic/investment) **Top assets mentioned** [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Incyte Corporation (INCY)](/topic/$incy) [Eli Lilly and Company (LLY)](/topic/$lly) [Akropolis (AKRO)](/topic/$akro) [Novo-Nordisk (NVO)](/topic/$nvo) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) ### Top Social Posts [#](/creator/twitter::1091405261741404162/posts) --- Top posts by engagements in the last XX hours "A look into the future Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M Lots of 👀👀👀 on this bispecific and the collaboration"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1945286039603454405) 2025-07-16 00:55:08 UTC 12.6K followers, 2434 engagements "On the topic of my recent buy of $SRPT thinking it was undervalued. I have learned from extensive focussed investing in biotechs that it is impt to invest in the science the clinical data and both the insight and trust in mgmt. Many examples in the rear view mirror but $INCY $REGN and $MDGL stand out for me. Huge trust after digging deep on the science innovation in clintrials and solving the problem of unmet medical need. All X huge in this regard. As to Sarepta one needs to know mgmt the history of the science and clintrial data and the "look em in the eyes of mgmt" to speak to the issue of"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947062077316571638) 2025-07-20 22:32:28 UTC 12.6K followers, 4957 engagements "On intra-pancreatic beta cell communication by which glucagon modulates insulin release"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1946610074014683351) 2025-07-19 16:36:22 UTC 12.6K followers, 1987 engagements "$ABVX Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 Enhancer in Moderate to Severely Active Ulcerative Colitis Just had to sell my X day held position (in an IRA) for a 5+ bagger some sort of record for me. More than made up for that $SRPT blunder of mine"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947792711584481575) 2025-07-22 22:55:45 UTC 12.6K followers, 3715 engagements "Own all three $ABVX $NKTR and $CRVS. That is my inflamm/onc strategy after some $REGN leaarnings. One key is the resistance mechanisms within patient subclasses. Another is being early on the science. Another is trying to figure out the role of Treg cells throughout the many valid disorders"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947825043163005111) 2025-07-23 01:04:13 UTC 12.6K followers, 1237 engagements "$MDGL Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom)"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1945470630725374164) 2025-07-16 13:08:38 UTC 12.6K followers, 2622 engagements "$MDGL Madrigal Pharmaceuticals Secures $XXX Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947741669496861047) 2025-07-22 19:32:55 UTC 12.6K followers, 1775 engagements "For the fwiw column I doubled up my position on the $NKTR weakness earlier today"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1945149631534371047) 2025-07-15 15:53:05 UTC 12.6K followers, 5976 engagements "On the timing of new(er) #MASH drugs to the fatty liver disease market esp F4's. $MDGL $AKRO $ETNB $LLY $NVO et al"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1941179181817266273) 2025-07-04 16:55:56 UTC 12.6K followers, 3770 engagements "@PJamess69 Perhaps this makes the potential acquirer(s) more anxious and now quicker at the draw to pay up Methinks also as to the buyout"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947788285864251533) 2025-07-22 22:38:10 UTC 12.6K followers, XXX engagements "Excellent thread on the Otsuka/Lundberg drug Rexulti by Dr Borecky. Just to review here is the prior efficacy summary as provided by Grok. $AXSM relevant. Clinical Trials for ApprovalOverview: Rexulti (brexpiprazole) is an atypical antipsychotic developed by Otsuka and Lundbeck approved by the FDA for major depressive disorder (MDD) as an adjunctive therapy schizophrenia and agitation associated with dementia due to Alzheimers disease. Its efficacy is thought to stem from partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors and antagonist activity at serotonin 5-HT2A"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1943077530245718427) 2025-07-09 22:39:18 UTC 12.6K followers, 3585 engagements ""Only dead fish go with the flow." David Ogilvy"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947129015644430531) 2025-07-21 02:58:27 UTC 12.6K followers, 1741 engagements "An analysis of PK/PD relationshipss of $VKTX VK2735 Ph2 efficacy and safety data"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947124026150617585) 2025-07-21 02:38:38 UTC 12.6K followers, 4133 engagements "Nice move by $MDGL on the patent extension news this morning. Methinks that the buyout will occur before the MAESTRO-NASH OUTCOMES trial in compensated cirrhosis is reported in 2027. Please do your own due diligence"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1945519554479763828) 2025-07-16 16:23:02 UTC 12.6K followers, 2990 engagements "@i_am_tyred I do thank you very much. I have a significant amount of $CRVS shares really like their covalent inhibitor approach and the drug MOA"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1945160672033054814) 2025-07-15 16:36:58 UTC 12.6K followers, XXX engagements "Axsome Therapeutics had their "Frontiers in Brain Health R&D Day" ystdy and I am parking the slide show. I am largely lured to $AXSM due to their expanding CNS pipeline and the potential of AXS-05 in Alzheimer's Disease Agitation amongst other reasons. I point out slides 17-41 on ADA for a thorough review of the ADVANCE and ACCORD series of Ph3 trials. The black-boxed #Rexulti (brexpiprazole) from Otsuka and Lundbeck is the only FDA-approved to treat agitation associated with dementia due to Alzheimer's disease. We shall see how the new FDA treats Axsome with this filing but my view is that"  [@JamesEKrause](/creator/x/JamesEKrause) on [X](/post/tweet/1947760109725356504) 2025-07-22 20:46:12 UTC 12.6K followers, 2743 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@JamesEKrause Biotech Jim
Biotech Jim posts on X about $mdgl, $regn, $srpt, $abvx the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +182%
- X Month XXXXXX +148%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +42%
Mentions: XX #
- X Months XX -XX%
- X Year XXX +120%
Followers: XXXXXX #
- X Week XXXXXX +0.50%
- X Month XXXXXX +1.60%
- X Months XXXXXX +7.90%
- X Year XXXXXX +16%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks finance agencies
Social topic influence $mdgl #4, $regn, $srpt, $abvx #48, $crvs, $nktr, drugs, $axsm, $951m, investment
Top assets mentioned Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Regeneron Pharmaceuticals Inc (REGN) Sarepta Therapeutics, Inc. (SRPT) Axsome Therapeutics, Inc (AXSM) Incyte Corporation (INCY) Eli Lilly and Company (LLY) Akropolis (AKRO) Novo-Nordisk (NVO) Viking Therapeutics, Inc (VKTX)
Top Social Posts #
Top posts by engagements in the last XX hours
"A look into the future Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M Lots of 👀👀👀 on this bispecific and the collaboration"
@JamesEKrause on X 2025-07-16 00:55:08 UTC 12.6K followers, 2434 engagements
"On the topic of my recent buy of $SRPT thinking it was undervalued. I have learned from extensive focussed investing in biotechs that it is impt to invest in the science the clinical data and both the insight and trust in mgmt. Many examples in the rear view mirror but $INCY $REGN and $MDGL stand out for me. Huge trust after digging deep on the science innovation in clintrials and solving the problem of unmet medical need. All X huge in this regard. As to Sarepta one needs to know mgmt the history of the science and clintrial data and the "look em in the eyes of mgmt" to speak to the issue of" @JamesEKrause on X 2025-07-20 22:32:28 UTC 12.6K followers, 4957 engagements
"On intra-pancreatic beta cell communication by which glucagon modulates insulin release" @JamesEKrause on X 2025-07-19 16:36:22 UTC 12.6K followers, 1987 engagements
"$ABVX Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod its First-in-Class Oral miR-124 Enhancer in Moderate to Severely Active Ulcerative Colitis Just had to sell my X day held position (in an IRA) for a 5+ bagger some sort of record for me. More than made up for that $SRPT blunder of mine" @JamesEKrause on X 2025-07-22 22:55:45 UTC 12.6K followers, 3715 engagements
"Own all three $ABVX $NKTR and $CRVS. That is my inflamm/onc strategy after some $REGN leaarnings. One key is the resistance mechanisms within patient subclasses. Another is being early on the science. Another is trying to figure out the role of Treg cells throughout the many valid disorders" @JamesEKrause on X 2025-07-23 01:04:13 UTC 12.6K followers, 1237 engagements
"$MDGL Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra (Resmetirom)" @JamesEKrause on X 2025-07-16 13:08:38 UTC 12.6K followers, 2622 engagements
"$MDGL Madrigal Pharmaceuticals Secures $XXX Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH" @JamesEKrause on X 2025-07-22 19:32:55 UTC 12.6K followers, 1775 engagements
"For the fwiw column I doubled up my position on the $NKTR weakness earlier today" @JamesEKrause on X 2025-07-15 15:53:05 UTC 12.6K followers, 5976 engagements
"On the timing of new(er) #MASH drugs to the fatty liver disease market esp F4's. $MDGL $AKRO $ETNB $LLY $NVO et al" @JamesEKrause on X 2025-07-04 16:55:56 UTC 12.6K followers, 3770 engagements
"@PJamess69 Perhaps this makes the potential acquirer(s) more anxious and now quicker at the draw to pay up Methinks also as to the buyout" @JamesEKrause on X 2025-07-22 22:38:10 UTC 12.6K followers, XXX engagements
"Excellent thread on the Otsuka/Lundberg drug Rexulti by Dr Borecky. Just to review here is the prior efficacy summary as provided by Grok. $AXSM relevant. Clinical Trials for ApprovalOverview: Rexulti (brexpiprazole) is an atypical antipsychotic developed by Otsuka and Lundbeck approved by the FDA for major depressive disorder (MDD) as an adjunctive therapy schizophrenia and agitation associated with dementia due to Alzheimers disease. Its efficacy is thought to stem from partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors and antagonist activity at serotonin 5-HT2A" @JamesEKrause on X 2025-07-09 22:39:18 UTC 12.6K followers, 3585 engagements
""Only dead fish go with the flow." David Ogilvy" @JamesEKrause on X 2025-07-21 02:58:27 UTC 12.6K followers, 1741 engagements
"An analysis of PK/PD relationshipss of $VKTX VK2735 Ph2 efficacy and safety data" @JamesEKrause on X 2025-07-21 02:38:38 UTC 12.6K followers, 4133 engagements
"Nice move by $MDGL on the patent extension news this morning. Methinks that the buyout will occur before the MAESTRO-NASH OUTCOMES trial in compensated cirrhosis is reported in 2027. Please do your own due diligence" @JamesEKrause on X 2025-07-16 16:23:02 UTC 12.6K followers, 2990 engagements
"@i_am_tyred I do thank you very much. I have a significant amount of $CRVS shares really like their covalent inhibitor approach and the drug MOA" @JamesEKrause on X 2025-07-15 16:36:58 UTC 12.6K followers, XXX engagements
"Axsome Therapeutics had their "Frontiers in Brain Health R&D Day" ystdy and I am parking the slide show. I am largely lured to $AXSM due to their expanding CNS pipeline and the potential of AXS-05 in Alzheimer's Disease Agitation amongst other reasons. I point out slides 17-41 on ADA for a thorough review of the ADVANCE and ACCORD series of Ph3 trials. The black-boxed #Rexulti (brexpiprazole) from Otsuka and Lundbeck is the only FDA-approved to treat agitation associated with dementia due to Alzheimer's disease. We shall see how the new FDA treats Axsome with this filing but my view is that" @JamesEKrause on X 2025-07-22 20:46:12 UTC 12.6K followers, 2743 engagements